… 15% of all lung cancers, representing approximately 372 … chemotherapeutic regimens, including amrubicin and irinotecan monotherapies. … Institute. Small cell lung cancer treatment (PDQ®)–health … of Lung Cancer—what limits limited disease? Lung Cancer. 2002 …

… patients with relapsed small cell lung cancer. Participants were treated with I … active chemotherapy comparator, including topotecan, amrubicin and lurbinectedin. In a joint … or metastatic non-small cell lung cancer. The rejection hinged on third …

… with extensive stage small cell lung cancer (ES-SCLC) with … aggressive nature, small cell lung cancer has long been particularly … ), topotecan (n = 185), or amrubicin (n = 23). The primary end … for extensive-stage small-cell lung cancer. FDA. November 19, 2025 …

… Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) ClinicalTrials.gov … chemotherapy—either topotecan, lurbinectedin, or amrubicin—(n = 255) until disease … Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …

… topotecan (n = 185), or amrubicin (n = 23). They were … chemotherapy (topotecan/amrubicin vs lurbinectedin). The trial … extensive stage small cell lung cancer. FDA. November 19, … Tarlatamab in small-cell lung cancer after platinum-based chemotherapy …

… with extensive-stage small cell lung cancer (ES-SCLC) with disease … patients with small cell lung cancer whose disease had grown … be topotecan, lurbinectedin or amrubicin. Patients stayed on treatment … For Some With Small Cell Lung Cancer.” CURE; Oct. 18, …

… with extensive stage small cell lung cancer (ES-SCLC) with disease progression … (SOC) chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression or unacceptable …

… topotecan (n = 185), or amrubicin (n = 23). The primary … previously treated small cell lung cancer receiving tarlatamab: results … treatment for small cell lung cancer (SCLC): primary analysis … Tarlatamab in small-cell lung cancer after platinum-based …

… of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1 … (Zepzelca; 21.2%), amrubicin (8.8%), DLL3-targeting … of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … with relapsed small cell lung cancer (IDeate-Lung02). Clinical …

… drugs, including topotecan, lurbinectedin, or amrubicin. Results from the interim analysis … planned for World Lung Cancer Day Coinciding with World Lung Cancer Day on Aug … of immunotherapy in small-cell lung cancer healthcare. Greek contribution draws …